PeptMentor
CalculatorsHow we source
PeptMentor
PeptMentor
Peptides
Eloralintide
Retatrutide
GHK-Cu
Pinealon
KPV
KLOW
All peptides
Compared
Eloralintide vs cagrilintide
Eloralintide vs retatrutide
Retatrutide vs tirzepatide
Guides and tools
Bac water for peptides
How to reconstitute peptides
Peptide reconstitution calculator
All guides
About
How we source
About
Editorial policy
Open the peptide calculator
PeptMentor

Plain answers about peptides and GLP-1 medicines. Every figure links to its source and says what kind of study it came from.

No dose advice. No sponsors, sellers or affiliate codes.

Peptides

  • Eloralintide
  • GHK-Cu
  • KLOW
  • KPV
  • Pinealon
  • Retatrutide
  • All peptides

Compare

  • Eloralintide vs cagrilintide
  • Eloralintide vs retatrutide
  • Retatrutide vs tirzepatide

Guides and tools

  • Peptide reconstitution calculator
  • Bac water for peptides
  • How to reconstitute peptides
  • All guides

About us

  • About
  • How we check facts
  • Editorial policy
  • Sources
  • Contact
© 2026 PeptMentor LLC. For information only, not medical advice. In an emergency call 911.
Medical disclaimerTermsPrivacyConsumer health data
  1. /Home
  2. /Blog
  3. /Retatrutide vs tirzepatide
Comparison

Retatrutide vs tirzepatide: weight and muscle loss

Muscle loss on tirzepatide vs retatrutide is one of the most searched questions about these two Eli Lilly drugs, along with which one causes more weight loss. Tirzepatide is approved; retatrutide is still in trials.

Illustration of two peptide chains on one cell: one reaching three receptors, the other reaching two
Illustration
Head-to-head not yet reportedTirzepatide approved; retatrutide not

Facts checked 2026-11-17 · by PeptMentor Team · How we source

On this page
The short answerSide by sideWeight-loss resultsMuscle and body compositionSide effectsAppetite and "food noise"Switching and taking them togetherClaims we checkedApproval status and timelineHow to read these numbersRetatrutide vs tirzepatide: questions people askSources

The short answer

Tirzepatide (Mounjaro, Zepbound) is FDA approved and acts on GIP and GLP-1 receptors. Retatrutide is not approved and adds the glucagon receptor[1]. In separate trials, the top doses lost −25.0% at 80 weeks[2] and −20.9% at 72 weeks[3]. The head-to-head trial, TRIUMPH-5[4], has not reported and has no body-composition outcome. No study shows that either drug spares muscle better. The only retatrutide head-to-head so far is against semaglutide, in type 2 diabetes.

Retatrutide
CellAnimalSmall humanHuman randomised trialApproved

Best evidence: human randomised trial

Retatrutide: human RCTs (phase 3). Not approved; Lilly plans to submit to FDA in Q1 2027.

Tirzepatide
CellAnimalSmall humanHuman randomised trialApproved

Best evidence: approved

Tirzepatide: approved drug with an FDA label.

Their head-to-head trial, TRIUMPH-5, has not reported, and it does not measure muscle. This page sets out what separate trials found on weight, body composition and side effects, and what no trial has tested.

Side by side

FeatureRetatrutideTirzepatide
DeveloperEli Lilly (LY3437943; nicknames "reta", "GLP-3")Eli Lilly (brands Mounjaro, Zepbound; nickname "tirz")
How it worksGIP, GLP-1 and glucagon receptors[1]GIP and GLP-1 receptors
StatusNot approved. Lilly plans to submit to FDA in Q1 2027 (Lilly press releases, 2026-07-23 and 2026-09-29). FDA says it cannot be compounded[5]FDA approved (Mounjaro for type 2 diabetes; Zepbound for weight management)
Main weight result (top dose)−25.0% vs −3.9% placebo at 80 weeks, treatment-regimen[2]−20.9% vs −3.1% placebo at 72 weeks[3]
Half-lifeAbout 6 days[6]Label check pending.
Stopped for side effects4.1–11.3% vs 4.9% placebo in TRIUMPH-1 (Lilly press release, 2026-05-21)4.3–7.1% vs 2.6% placebo in SURMOUNT-1[3]
Signature side effectsDysesthesia (skin burning or tingling); heart rate rose with dose[7]Per-arm rates are not included here.
Body-composition dataPhase 2 substudy in type 2 diabetes, 36 weeks[8]SURMOUNT-1 substudy, 72 weeks[9]

Cross-trial table. TRIUMPH-1 and SURMOUNT-1 differ in length (80 vs 72 weeks) and population, so one row is not a head-to-head result.

Weight-loss results

Separate trials: not a head-to-head comparison

Retatrutide, TRIUMPH-1: weight lost at 80 weeks (% of body weight) Retatrutide arm Placebo

Scale: 0–30%

4 mg17.6% vs 3.9%
9 mg23.7% vs 3.9%
12 mg25% vs 3.9%

Treatment-regimen estimand, n = 2,339 adults with obesity, no diabetes[2].

Tirzepatide, SURMOUNT-1: weight lost at 72 weeks (% of body weight) Tirzepatide arm Placebo

Scale: 0–30%

5 mg15% vs 3.1%
10 mg19.5% vs 3.1%
15 mg20.9% vs 3.1%

Adults with obesity, no diabetes[3]. Separate trial from the chart above: different length and estimand reporting. Trial arms, not dose advice; milligrams do not convert between these drugs.

What TRIUMPH-5 will and won't tell us. TRIUMPH-5[4] randomises about 800 people with obesity to retatrutide or tirzepatide. Its primary outcome is percent weight change at week 80. Secondary outcomes cover BMI, waist, lipids, blood pressure, HbA1c, fasting insulin and quality of life. It has no DXA or other body-composition outcome, so it will not answer the muscle question. When we checked the registry on 2026-11-17 it was active and not recruiting, primary completion was estimated for November 2026, and no results were posted.

The only retatrutide head-to-head so far is against semaglutide. In TRANSCEND-T2D-2, an open-label 80-week trial in type 2 diabetes, weight fell −19.5% and −20.9% on retatrutide 9 and 12 mg vs −9.4% on Ozempic 2 mg (efficacy estimand; Lilly press release, 2026-10-28)[10]. It is not yet peer-reviewed. For context, tirzepatide beat semaglutide head-to-head in SURMOUNT-5: −20.2% vs −13.7% at 72 weeks[11].

Muscle and body composition

No study has measured muscle or lean mass on retatrutide and tirzepatide in the same trial. Each drug has one DXA substudy, in different people, over different lengths of time.

Separate trials: not a head-to-head comparison

Tirzepatide, SURMOUNT-1 DXA substudy: change at week 72 (% decrease) Tirzepatide Placebo

Scale: 0–40%

Body weight21.3% vs 5.3%
Fat mass33.9% vs 8.2%
Lean mass10.9% vs 2.6%

n = 160[9]. About 75% of the weight lost was fat and 25% lean mass, a similar split in the tirzepatide and placebo groups.

Retatrutide, phase 2 type 2 diabetes DXA substudy: fat mass at week 36 (% decrease) Retatrutide 12 mg Placebo

Scale: 0–40%

Fat mass23.2% vs 4.5%

103 completers[8]. The authors describe the lean-mass share of weight lost as "similar to other obesity treatments"; we have not found a per-arm lean figure to chart.

Lean mass is not the same as muscle
DXA lean mass includes water, organs and connective tissue as well as muscle. A fall in lean mass does not tell you how much muscle was lost, and neither substudy measured strength or function.

So the honest answer to "does retatrutide preserve muscle better than tirzepatide?" is that no data exist to say. The two substudies differ in population (with and without type 2 diabetes), length (36 vs 72 weeks) and what they report. A claim that retatrutide is "muscle-sparing" has no source.

Side effects

EventRetatrutide 4 / 9 / 12 mgPlaceboTirzepatide (SURMOUNT-1)Placebo
Nausea28.6 / 38.4 / 42.4%14.8%Data are not included here.-
Vomiting10.6 / 22.8 / 25.3%4.8%Data are not included here.-
Dysesthesia (skin burning or tingling)5.1 / 12.3 / 12.5%0.9%Data are not included here.-
Stopped for side effects4.1 / 6.9 / 11.3%4.9%4.3–7.1%[3]2.6%

Each drug against its own trial's placebo. Retatrutide figures from Lilly's TRIUMPH-1 release (2026-05-21); paper:[2].

In retatrutide's phase 2 trial, heart rate rose with dose, peaked at week 24 and then declined[7]. Across phase 3, dysesthesia ranged from 4.5% to 20.9% by arm; details are on the retatrutide page.

Appetite and "food noise"

No trial has measured appetite or "food noise" on the two drugs head-to-head. Online threads often say tirzepatide is better for appetite and retatrutide for metabolism. That is what people report, not a trial finding.

One study analysed Reddit posts from 7,823 people describing non-approved retatrutide use: 17.1% reported increased appetite[12]. These are self-reports about products whose identity and dose could not be checked, so they say nothing reliable about the trial drug.

Switching and taking them together

Switching. No trial has tested moving from tirzepatide to retatrutide. Retatrutide's phase 3 trials excluded people who had used weight-loss drugs in the 90 days before screening[13], and there is no official milligram conversion between the two. The retatrutide page covers how the trials started people on the drug.

Together. No trial has given tirzepatide and retatrutide together.

What no trial has tested
A reported head-to-head of retatrutide and tirzepatide. Taking them together. Switching from one to the other. Body composition on both drugs in one trial. Retatrutide beyond 104 weeks.

ClinicalTrials.gov, searched 2026-11-17

Claims we checked

ClaimVerdictWhat the source says
Retatrutide beat tirzepatide by 23% in a phase 3 head-to-head (a ranking comparison page)FalseTRIUMPH-5 had posted no results on 2026-11-17[4]
Retatrutide trials started at 0.25 mg, given IV (same page)FalsePhase 3 trials started at 2 mg, under the skin (Lilly press releases on TRIUMPH-1 and TRIUMPH-4)
Retatrutide preserves muscle better than tirzepatideNo sourceNo trial has compared body composition on the two drugs
Retatrutide and semaglutide have never been tested head-to-head (search summary)Out of dateTRANSCEND-T2D-2 reported on 2026-10-28[10]

Approval status and timeline

  1. 2022

    SURMOUNT-1 published: tirzepatide −15.0% to −20.9% at 72 weeks.

    Jastreboff et al., NEJM 2022[3] Human randomised trial
  2. 2025

    SURMOUNT-5 published: tirzepatide −20.2% vs semaglutide −13.7% at 72 weeks.

    NEJM 2025[11] Human randomised trial
  3. 2025-12-11

    Retatrutide's first phase 3 readout (TRIUMPH-4, knee osteoarthritis).

    Lilly press release; paper NEJM 2026[14] Company press release
  4. 2026-07-23

    TRIUMPH-2 and TRIUMPH-3 toplines; Lilly says it plans to submit retatrutide to FDA in Q1 2027.

    Lilly press release[15] Company press release
  5. 2026-09-29

    TRIUMPH-1 published in NEJM.

    Jastreboff et al., NEJM 2026[2] Human randomised trial
  6. 2026-10-01

    FDA states retatrutide cannot be used in compounding under federal law.

    FDA statement on unapproved GLP-1 drugs[5] Regulator
  7. 2026-10-28

    TRANSCEND-T2D-2: first retatrutide head-to-head (vs semaglutide), topline.

    Lilly press release[10] Company press release
  8. 2026-11 (est.)

    TRIUMPH-5 (retatrutide vs tirzepatide) estimated primary completion. No results yet.

    ClinicalTrials.gov[4] Trial registry

We will update this page when TRIUMPH-5 reports. FDA has also sent warning letters to firms selling or repackaging retatrutide, including a January 2026 letter to a facility that repackaged tirzepatide and retatrutide (FDA warning letter to GenoGenix LLC, 2026-01-20).

How to read these numbers

Cross-trial figures are not head-to-head
The retatrutide and tirzepatide figures on this page come from separate trials with different lengths, populations and estimands. Lilly releases lead with the efficacy estimand; journals usually lead with the treatment-regimen estimand. Until TRIUMPH-5 reports, no trial can say which drug causes more weight loss.

Retatrutide vs tirzepatide: questions people ask

Direct answers to what people search for. Bracketed numbers point to the sources at the end; the sections above have the detail.

Does retatrutide work better than tirzepatide?

The trial that will answer this, TRIUMPH-5, has not reported. In separate trials, top doses lost −25.0% at 80 weeks on retatrutide and −20.9% at 72 weeks on tirzepatide, which is not a head-to-head result.

Does retatrutide cause less muscle loss than tirzepatide?

No data show that. Each drug has one DXA substudy in different people over different lengths, and TRIUMPH-5 does not measure body composition[4].

Can you build muscle on retatrutide?

No retatrutide trial has measured muscle growth, strength or function. Its body-composition substudy measured fat and lean mass by DXA, and lean mass is not the same as muscle[8].

Is there a head-to-head trial, and when will it report?

Yes: TRIUMPH-5. On 2026-11-17 the registry estimated primary completion for November 2026 and showed no results[4]. Lilly has not announced a readout date.

Is retatrutide better than Ozempic?

In TRANSCEND-T2D-2, people with type 2 diabetes lost −20.9% on retatrutide 12 mg vs −9.4% on Ozempic 2 mg at 80 weeks (Lilly press release, 2026-10-28)[10]. The trial was open-label and is not yet peer-reviewed.

Which suppresses appetite more?

No trial has compared appetite or "food noise" on the two drugs. Online comparisons are personal reports.

Can you take tirzepatide and retatrutide together?

No trial has tested the two together (ClinicalTrials.gov, searched 2026-11-17).

Is there a dose conversion between them?

No. Lilly has published no milligram conversion, and milligrams of different molecules are not equivalent. See the retatrutide page for what the trials did.

Sources

  1. 1.Coskun et al. Retatrutide discovery. Cell Metab 2022. PMID 35985340 Animal
  2. 2.Jastreboff et al. TRIUMPH-1. NEJM 2026. PMID 42814954 Human randomised trial
  3. 3.Jastreboff et al. SURMOUNT-1. NEJM 2022. PMID 35658024 Human randomised trial
  4. 4.TRIUMPH-5 trial record, NCT06662383 (checked 2026-11-17) Trial registry
  5. 5.FDA: concerns with unapproved GLP-1 drugs used for weight loss (2026-10-01) Regulator
  6. 6.Urva et al. Retatrutide phase 1b (half-life). Lancet 2022. PMID 36354040 Small human study
  7. 7.Jastreboff et al. Retatrutide phase 2. NEJM 2023. PMID 37366315 Human randomised trial
  8. 8.Coskun et al. Retatrutide phase 2 body-composition substudy. Lancet Diabetes Endocrinol 2025. PMID 40609566 Human randomised trial
  9. 9.Look et al. SURMOUNT-1 body-composition substudy. 2025. PMID 39996356 Human randomised trial
  10. 10.TRANSCEND-T2D-2 trial record, NCT06260722 (results via Lilly press release, 2026-10-28) Company press release
  11. 11.SURMOUNT-5, tirzepatide vs semaglutide. NEJM 2025. PMID 40353578 Human randomised trial
  12. 12.Sehgal et al., JAMA Netw Open 2026
  13. 13.TRIUMPH-1 eligibility
  14. 14.Schnitzer et al. TRIUMPH-4 and TRIUMPH-1-OA. NEJM 2026. PMID 43001755 Human randomised trial
  15. 15.Lilly press release; trial record NCT05929079
On this pageThe short answerSide by sideWeight-loss resultsMuscle and body compositionSide effectsAppetite and "food noise"Switching and taking them togetherClaims we checkedApproval status and timelineHow to read these numbersRetatrutide vs tirzepatide: questions people askSources